[go: up one dir, main page]

EP2673379A2 - Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation - Google Patents

Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation

Info

Publication number
EP2673379A2
EP2673379A2 EP12708501.7A EP12708501A EP2673379A2 EP 2673379 A2 EP2673379 A2 EP 2673379A2 EP 12708501 A EP12708501 A EP 12708501A EP 2673379 A2 EP2673379 A2 EP 2673379A2
Authority
EP
European Patent Office
Prior art keywords
seq
prostate cancer
marker
protein
marker sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12708501.7A
Other languages
German (de)
English (en)
Inventor
Angelika Lueking
Axel Kowald
Georg Bartsch
Helmut Klocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to EP12708501.7A priority Critical patent/EP2673379A2/fr
Publication of EP2673379A2 publication Critical patent/EP2673379A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to new marker sequences for prostate cancer (syn: prostate cancer) excluding prostate inflammatory diseases or diabetes or
  • Polymorbidity and its diagnostic use including a method of screening for potential drugs for such prostate diseases by means of these marker sequences. Furthermore, the invention relates to a diagnostic device
  • Protein biochips are gaining an increasing industrial
  • Protein biochips require the necessary proteins to be available. In particular,
  • the cDNA of a particular tissue in a bacterial or a eukaryotic expression vector such as yeast, cloned.
  • the vectors used for the expression are generally characterized by the fact that they carry inducible promoters, with which the timing of protein expression can be controlled.
  • expression vectors have sequences for so-called
  • Affinity epitopes or proteins on the one hand for the specific detection of the recombinant fusion proteins by means of a directed against the affinity epitope
  • Antibody on the other hand becomes the specific one
  • PSA prostate-specific antigen
  • Prostate but not for a tumor, but may also be increased in inflammation, benign prostatic hyperplasia, a urinary retention or for no apparent reason. A value above 4 ng / ml is already in need of clarification.
  • Prostate cancer patients is possible. Furthermore, it is disadvantageous in the prior art that due to other indications, such as prostatectivitis or diabetes, false-positive
  • Marker sequences can be identified.
  • WO 2009/080017 discloses marker sequences for neurodegenerative disorders and their use.
  • the sequences disclosed in WO 2009/080017 were correspondingly obtained by a method without using samples of prostate cancer patients
  • US 2004/259086 relates to compositions, kits and methods for the detection, characterization, prevention and treatment of prostate cancer in humans. A number of marker sequences whose expression levels correlate with prostate cancer were used. However, US 2004/259086 does not disclose Marker sequences, for the diagnosis of prostate cancer excluding prostate inflammatory diseases, diabetes, polymorbidity. The marker sequences in US 2004/259086 were obtained by subtracting cDNA libraries prepared from the mRNA of patients with benign prostatic hyperplasia and the cDNA prepared from the mRNA of patients with prostate cancer ([0339] et seq. In US 2004/259086). Another marker sequences in US 2004/259086 were obtained by subtracting cDNA libraries prepared from the mRNA of patients with benign prostatic hyperplasia and the cDNA prepared from the mRNA of patients with prostate cancer ([0339] et seq. In US 2004/259086). Another marker sequences in US 2004/259086 were obtained by subtracting cDNA libraries prepared from the mRNA of patients
  • the object of the present invention is to provide improved marker sequences and their diagnostic use for the treatment of prostate cancer, wherein
  • Prostatex inflammation and / or diabetes disease occurs.
  • Prostate carcinoma in particular by means of a protein biochip.
  • the invention relates to the use of
  • Marker sequences for the diagnosis of prostate carcinoma wherein at least one marker sequence of a cDNA selected from the group SEQ 1 - 246 or in each case a protein encoded thereby or in each case a partial sequence or fragment thereof
  • marker sequences according to the invention to or from a patient to be examined.
  • the marker sequences of the invention could by means of differential screening of samples and healthy
  • prostate inflammatory disease s
  • the marker sequences of the invention are tested against patient samples of prostate inflammatory diseases (e.g., all forms of prostatic hyperplasia, prostatitis) or diabetes on a protein biochip.
  • prostate inflammatory diseases e.g., all forms of prostatic hyperplasia, prostatitis
  • diabetes e.g., all forms of prostatic hyperplasia, prostatitis
  • Subgroup Patients can be determined (hereinafter "subgroup") . These marker sequences can selectively be the subgroup - i.e. the patients within the group of patients with
  • patients can thus be found subgroups within the group of prostate cancer patients and the appropriate Treatment / Therapy for this subgroup can be selected while patients with prostate cancer who are not
  • Subgroup belong to be excluded from inappropriate therapies.
  • the invention is therefore a use of
  • Prostate inflammatory disease (s) and / or diabestes and wherein at least one marker sequence of a cDNA selected from the group SEQ 1 - 246 and / or SEQ 247-452 or each protein encoded thereby or in each case a partial sequence or fragment thereof to or from one too
  • the invention therefore also relates to the use of the marker sequences for the diagnosis of prostate cancer
  • Marker sequence (s) has been identified with a method comprising the a) identification of marker sequence candidates by differential screening with protein biochips, for example two protein biochips, each from a cDNA expression library of a patient with
  • Prostatectomy for inflammation and / or samples from patients with diabetes.
  • the samples used for validation come from
  • Prostate inflammatory diseases and / or have diabetes but no prostate cancer Prostate inflammatory diseases and / or have diabetes but no prostate cancer.
  • One embodiment of the invention relates to the use of the marker sequences according to the invention for the diagnosis of
  • Marker sequences for example 10 to 20 or 30 or more different marker sequences on or from one to
  • One embodiment of the invention relates to the use of the marker sequence (s) according to the invention for the diagnosis of
  • polymorbidity wherein at least one of the marker sequences is selected from the group SEQ ID No. 247, SEQ ID No. 250, SEQ ID NO. 290 or a by SEQ ID No. 247, SEQ ID No. 250, SEQ ID No. 290 encoded protein or a partial sequence or a fragment of SEQ ID No. 247, SEQ ID No. 250, SEQ ID No. 290. Further preferred are therefore the corresponding
  • Marker sequences selected from the group SEQ ID No. 1, SEQ ID no. 4 and SEQ ID No. 44. or a SEQ ID No. 1, SEQ ID No. 4, SEQ ID No. 44 encoded protein or a partial sequence or a fragment of SEQ ID No. 1, SEQ ID No. 4, SEQ ID NO. 44th
  • marker sequences SEQ ID no. 249, SEQ ID No. 255, SEQ ID No. 271, SEQ ID No.
  • SEQ ID No. 341 wherein at least one of the marker sequences is selected from the group SEQ ID No. 249, SEQ ID No. 255, SEQ ID no. 271, SEQ ID No. 301, SEQ ID No. 341 or a by SEQ ID NO. 249, SEQ ID No. 255, SEQ ID No. 271, SEQ ID No. 301, SEQ ID No. 341 encoded protein or a partial sequence or a fragment of SEQ ID No. SEQ ID No. 249, SEQ ID No. 255, SEQ ID No. 271, SEQ ID No. 301, SEQ ID No.341. Preference is therefore further given to the corresponding marker sequences selected from the group SEQ ID No. 3, SEQ ID No.
  • An embodiment of the invention relates to the use of the marker sequence (s) according to the invention for the diagnosis of
  • ventral antigen 2 (NOVA2), syntaxin 18 (STX18), heat shock (Heatshock) 105kDa / 110kDa protein 1 (HSPH1) or a nucleic acid encoding it or a partial sequence or a
  • a fragment thereof is determined on or from a patient to be examined and wherein the marker sequence (s) with a
  • a method has been identified, comprising the steps of a) identification of marker sequence candidates by differential screening with protein biochips, for example two protein biochips, each from a cDNA expression library of a patient with
  • Prostatectomy for inflammation s
  • samples from patients with diabetes s
  • marker sequence of a cDNA in each case selected from the group SEQ 1 - 246 and / or SEQ 247-452 or in each case a protein encoded thereby or in each case a partial sequence or fragment thereof as a diagnostic agent, wherein the marker sequence (s) was identified by a method ( n), comprising the steps of a) identification of marker sequence candidates by differential screening with protein biochips, for example two protein biochips from each cDNA expression library of a patient with
  • Prostatectomy for inflammation s
  • samples from patients with diabetes s
  • the invention also provides a method for the diagnosis of prostate cancer excluding
  • the invention also provides a method for
  • Stratify in particular for risk stratification, or for therapy control of a patient with prostate cancer excluding prostate inflammatory diseases or diabetes or polymorbidity, wherein at least one
  • Prostatectomy for inflammation s
  • samples from patients with diabetes s
  • the invention also relates to an assay, protein biochip consisting of an arrangement containing at least one
  • Marker sequence (s) has been identified by a method comprising the steps a) Identification of marker sequence candidates by differential screening with protein biochips, for example two protein biochips, each from a cDNA expression library of a patient with
  • Prostatectomy for inflammation s
  • samples from patients with diabetes s
  • the invention also provides a diagnostic for the diagnosis of prostate cancer excluding
  • Polymorbidity containing at least one marker sequence each selected from the group SEQ 1 - 246 and / or SEQ ID 247 - 452 or in each case a protein encoded thereby or in each case a partial sequence or fragment thereof, wherein the
  • Marker sequence (s) has been identified by a method comprising the steps of a) identifying marker sequence candidates by differential screening with protein biochips, for example two protein biochips each from a cDNA expression library of a patient with
  • Prostatectomy for inflammation s
  • prostate cancer includes only the indication prostate cancer or prostate cancer under
  • Prostate hyperplasia especially benign prostate hyperplasia. Included in the invention is the presence of one or more different prostate inflammatory diseases.
  • diabetes is understood to mean, for example, “diabetes mellitus", in particular type II diabetes mellitus (insulin resistance), a chronic one
  • Metabolic disease in which the production of insulin in the ß-cells of the islets of Langerhans is disturbed in the pancreas or insulin is indeed present on his
  • Diabetic disease is distinguished between prediabetes, in which it comes only in its final stage to a laboratory-chemically detectable "disturbed glucose tolerance", and the actual manifest diabetes mellitus.At the beginning of the prediabetic phase of the disease is the
  • diabetes is also understood to mean type I diabetes.
  • the invention relates to such marker sequences that co-polymorphism or polymorbidity with other indications, such as
  • Prostatic inflammation s
  • diabetes in all forms
  • At least 2 to 5 or 10 preferably 30 to 50 marker sequences or 50 to 100 or more marker sequences on or from one to
  • the marker sequences according to the invention can also be combined, supplemented or extended with known biomarkers for this indication. Also particularly preferred are such markers as disclosed in WO2010 / 000874.
  • the determination of the marker sequences takes place outside the human body and the determination is made in an ex vivo / in vitro diagnosis.
  • the invention relates to the use of marker sequences as diagnostics, wherein at least one marker sequence of a cDNA is selected from the group SEQ 1 - 246 or in each case a protein coding therefor or in each case a partial sequence or fragment thereof.
  • the invention relates to a method for the diagnosis of prostate carcinoma, wherein a.) At least one marker sequence of a cDNA selected from the group SEQ 1 - 246 or a respective coding protein or a partial sequence or fragment thereof is applied to a solid support and b. ) with body fluid or tissue extract one
  • the invention also relates to diagnostics for
  • SEQ 1-18 are particularly preferred and SEQ 19-56 are preferred, again lower numerical values being preferred.
  • the detection of such an interaction can, for example, by a probe, in particular by an antibody
  • the invention also has the object of providing a diagnostic device or assay, in particular a protein biochip, which allows for diagnosis or examination of prostate cancer.
  • the invention relates to a method for
  • Prostate carcinoma wherein at least one marker sequence of a cDNA selected from the group SEQ 1 - 246 or in each case a protein coding therefor is determined on a patient to be examined.
  • therapy control also includes the classification of patients in responders and non-responders with respect to a therapy or its
  • Diagnosis in the sense of this invention means the positive detection of a prostate carcinoma by means of
  • diagnosis includes medical diagnostics and related
  • diagnosis also includes the differential diagnosis of prostate cancer by means of the marker sequences according to the invention and the prognosis of a prostate carcinoma.
  • Stratification also: stratification
  • therapy control in the sense of this invention means that the inventive method decisions for the treatment and therapy of the
  • Patients are allowed, whether it is the hospitalization of the patient, use, effect and / or dosage of one or more drugs, a therapeutic measure or the
  • the term "stratification" includes in particular the
  • patient is understood to mean any test subject - human or mammal - with the proviso that the test person is examined for prostate carcinoma.
  • marker sequences in the sense of this invention means that the cDNA or the respective polypeptide or protein obtainable therefrom are significant for prostate carcinoma
  • polypeptide or protein interacts with a sample, e.g. Substances from the body fluid or tissue extract of a patient with
  • prostate cancer e.g., antigen (epitope) / antibody (paratope)
  • At least one marker sequence of a cDNA selected from the group SEQ. 1-246 or in each case a protein coding therefor or in each case a partial sequence or fragment thereof to or from a patient to be examined is determined" that an interaction between the body fluid or
  • Marker sequences is detected. Such an interaction is for example a bond, in particular a binding substance at least one marker sequence according to the invention or, in the case of a cDNA, the hybridization with a suitable substance under selected conditions, in particular stringent
  • Hybridization conditions are: hybridization in 4 x SSC at 65 ° C (alternatively in 50% formamide and 4X SSC at 42 ° C), followed by several washes in 0.1 x SSC at 65 ° C for a total of about one hour.
  • An example of less stringent hybridization conditions is hybridization in 4 x SSC at 37 ° C, followed by several washes in 1 x SSC
  • Body fluid in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid or a tissue extract of the patient.
  • Samples of patients or subjects include, for example, body fluid, especially blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid, or a tissue extract of the patient or subject.
  • the marker sequences of the invention may be present at a significantly higher or lower expression rate or concentration indicative of prostatic carcinoma. In this case, the relative.
  • the marker sequences have a recognition signal which is addressed to the substance to be bound (for example antibodies,
  • the recognition signal is preferably an epitope and / or paratope and / or hapten and, for a cDNA, a hybridization or hybridization protein
  • the marker sequences of the invention are the subject of Table A and can by the respective cited
  • the invention also relates to the full-length sequences of the markers according to the invention and indeed as defined in Table 1 on the known database entry according to Table A, hereinafter called SEQ ID NOS 247-452, see also that
  • marker sequences SEQ 1-246 are in accordance with the invention.
  • SEQ 247-260 and SEQ 261-294 are prefers . Further preferred are SEQ 247-260 and SEQ 261-294.
  • Marker sequences preferred that have P values less than or equal to 0.2, preferably less than or equal to 0.15, more preferably less than or equal to 0.1.
  • Embodiment of the invention are the marker sequences SEQ ID No. 247, 250, 290, partial sequences, fragments or homologs and the peptides / proteins encoded thereby.
  • SEQ ID no. 247 P value: 0.1053
  • SEQ ID No. 250 P value:
  • P value indicates the probability that a match was found in the database.
  • P-value see, for example, http://www.ncbi.nlm.nih.gov/books/NBK62051/.
  • the marker sequences also include such
  • Amino acid sequence such as chemical modification, such as
  • marker sequences Includes marker sequences.
  • those partial sequences having an identity of 99% or more, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, especially 85%, 80% or 70% with have the marker sequences according to the invention and for the inventive use - the detection
  • Polymorbidity - are suitable. (so-called “homologues", homologous marker sequences) .Hiomologists may use protein or
  • Partial sequences are also those sequences which have 50 to 100 nucleotides, 70-120 nucleotides of a sequence of SEQ 1-452, or peptides obtainable therefrom.
  • Marker sequence can be represented in different amounts in one or more areas on a solid support. This allows a variation of the sensitivity.
  • the regions can each have an entirety of marker sequences, ie a sufficient number of different marker sequences, in particular 2 to 5 or 10 or more and, if appropriate, further nucleic acids and / or proteins, in particular biomarkers. However, at least 96 to 25,000 (numerically) or more from different or identical marker sequences and further nucleic acids and / or proteins, in particular, are preferred
  • Biomarkers Further preferred are more than 2,500, more preferably 10,000 or more different or the same
  • Marker sequences and optionally other nucleic acids and / or proteins, in particular biomarkers are optionally other nucleic acids and / or proteins, in particular biomarkers.
  • Another object of the invention relates to an array of marker sequences containing at least one marker sequence of a cDNA selected from the group SEQ 1-452 or in each case a protein coding therefor.
  • the group SEQ 1-452 or in each case a protein coding therefor.
  • “arrangement” synonymously means “array” and insofar as this "array” is used to identify substances on marker sequences, this is to be understood as meaning an “assay” or a diagnostic device.
  • the arrangement is designed such that those represented on the assembly
  • Marker sequences are in the form of a grid on a solid support. Further, such arrangements are preferred which allow a high density array of protein binders and spotting the marker sequences. Such high density spotted assemblies are disclosed, for example, in WO 99/57311 and WO 99/57312, and may be advantageously used in a robotic automated high throughput method.
  • test or diagnostic device also includes such
  • Embodiments of a device such as ELISA, bead-based assay, line assay, Western blot, immunochromatographic methods (eg so-called lateral flow immunoassays) or similar immunological single or multiplex detection methods.
  • a protein biochip in the sense of this Invention is the systematic arrangement of proteins on a solid support.
  • the marker sequences of the assembly are fixed to a solid support, but preferably spotted or immobilized even printed, i. applied reproducibly.
  • One or more marker sequences can be duplicated in the totality of all
  • Marker sequences are present and available in different quantities related to a spot. Furthermore, the
  • Marker sequences on the solid support may be standardized (e.g., by serial dilution series of e.g.
  • the invention relates to an assay or protein biochip consisting of an array containing marker sequences according to the invention.
  • the marker sequences are present as clones.
  • Such clones can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al., 1998 (supra)).
  • such expression libraries become
  • Obtained marker sequences are obtained. These expression vectors preferably contain inducible promoters. The induction of
  • Expression can e.g. by means of an inductor, such as IPTG.
  • IPTG inductor
  • Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol 2003 Jan; 60 (5): 523-33).
  • Expression libraries are known to the person skilled in the art, these can be prepared according to standard works, such as Sambrook et al., Molecular Cloning, Laboratory Handbook, 2nd edition (1989), CSH press, Cold Spring Harbor, New York Further preferred are such expression libraries
  • tissue specific eg human tissue, in particular human organs
  • expression libraries are also included according to the invention, which can be obtained by exon trapping. Instead of expression library can be spoken synonymously from an expression bank.
  • protein biochips or corresponding expression libraries which have no redundancy (so-called: Uniclone® library) and can be prepared, for example, according to the teachings of WO 99/57311 and WO 99/57312. These preferred Uniclone libraries have a high content of non-defective, fully expressed proteins of a cDNA expression library.
  • the clones may not be such as transformed bacteria, recombinant phage or transformed cells of mammals, insects, fungi, yeasts or plants.
  • the clones are fixed on a solid support, spotted or immobilized.
  • the invention relates to an arrangement, wherein the
  • Marker sequences are present as clones.
  • the marker sequences may be in the form of a fusion protein in the particular form
  • At least one affinity epipope or "tag” contains.
  • the tag may be one such as c-myc, His-tag, Arg-tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or Strep tag, HAT tag, NusA, S-tag, SBP tag , Thioredoxin, DsbA, a fusion protein, preferably a cellulose-binding one
  • solid support includes embodiments such as a filter, a membrane, a magnetic or fluorophore-labeled bead
  • Silicon wafer glass, metal, plastic, a chip, a Mass spectrometric target or a matrix.
  • a filter is preferred according to the invention.
  • the filter is PVDF, nitrocellulose or nylon (e.g., Immobilon P Millipore, Protran Whatman, Hybond N + Amersham).
  • this corresponds to a grid having the order of a microtiter plate (8-12 wells strips, 96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
  • the invention relates to an assay or protein biochip for identifying and
  • the invention further relates to a method for identifying and characterizing a substance for prostate carcinoma, characterized in that an arrangement or assay according to the invention is brought into contact with a.) At least one substance to be investigated and b.) A binding success
  • the substance to be tested may be any native or non-native biomolecule, a synthetic chemical
  • Antigen / antibody or corresponding "means for detecting the binding success" can, for example, by means of
  • reporter enzymes such as alkaline
  • a readout is e.g. by means of a microarray laser scanner, a CCD camera or visually.
  • the invention relates to a drug / drug or prodrug designed for prostate cancer and obtainable through the use of the prostate cancer
  • the invention also relates to the use of an inventive arrangement or an assay for screening prostate cancer drugs. Therefore, in another embodiment, the invention also relates to a target for the treatment and therapy of
  • Prostate carcinoma each selected from the group SEQ 1 - 246 or each protein coding therefor.
  • the invention also relates to the use of the invention
  • Marker sequences preferably in the form of an arrangement, as an affinity material for performing an apheresis or iwS. a blood wash, wherein substances from bodily fluids of a patient with prostate cancer, such as blood or plasma, to bind the marker sequences according to the invention and consequently the body fluid can be selectively withdrawn.
  • Corresponding devices are known in the art, e.g. chromatographic devices containing beads, spheres or chromatographic material, e.g. in a column having the marker sequences of the invention and therefore e.g. (Auto) can selectively withdraw antibodies.
  • FIG. 1 shows the differential screening between two protein biochips from in each case one cDNA expression bank of a patient and one healthy subject.
  • Differential clones are detected by fluorescence labeling and evaluated bioinformatorisch.
  • Intensity data performed.
  • an internal standard is used, which is spotted on each chip. Since a p-value is calculated for each antigen, methods for correcting the multiple testing are used.
  • FDR False Discovery Rate
  • the data are used to classify the sera.
  • different multivariate methods are used. These are methods from the statistical
  • Threshold method which is suitable for both classification and visual representation of the data.
  • PRKRA PRKRA activator
  • SCAP SREBP cleavage-activating protein
  • transcript variant 2 (LOC731567)
  • HMGN4 High Mobility Group nucleosomal binding domain 4
  • G protein pathway suppressor 1 G protein pathway suppressor 1
  • FAM53B NM_014661 gil4757715
  • gil53759121 Adenomatosis polyposis coli (APC) NM_000038 gil57242754 calsyntenin 1 (CLSTN1), transcript variant 2 NM_014944 gil7705480 ubiquitin-fold modifier conjugating enzyme 1 (UFC1) NM_016406 gil82659090 Staufen, RNA binding protein, homologue 1 (Drosophila) (STAU1), NM_0010373
  • gil33286421 Pyruvate kinase, muscle (PKM2), transcript variant 3 NM_182471 gil34147626 Zinc finger protein 447 (ZNF447) NM_023926 gil38176162 Ring finger protein 130 (RNF130) NM_018434 gil47933378 N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA) NM_003827 gil49472815 Fascin homolog 1 , actin-bundling protein (Strongylocentrotus NM_003088
  • RPL6 Ribosomal protein L6
  • NBP2 Nucleotide binding protein 2
  • NM_012225 gil73622128 Caspase 6, apoptosis-related cysteine peptidase (CASP6), transcript NM_001226
  • HNRPA1 Heterogeneous nuclear ribonucleoprotein AI
  • transcript NM_031157 HNRPA1
  • gil94721349 islet cell autoantigen 1, 69kDa (ICA1), transcript variant 2 NM_004968 gil42794610 6-phosphogluconolactonase (PGLS), NM_012088 gil 113420239 Similar to block of proliferation 1 (LOC727967) XM_0011262
  • NM_0010059 mi togen-activated protein kinase 11 (MAPK11) NM_002751 gil50233802 NDRG family member 4 (NDRG4) NM_020465 gil56090145 Hypothetical LOC339123 (LOC339123), NM_0010059
  • NM_0010053 gil31317308 phosphatidylinositol 4-phosphate 5-kinase, type I, gamma (PIP5K1C) NM_012398 gil46048184 Sterile alpha motif domain containing 10 (S AMD 10) NM_080621 gil56549124 Dynamin 2 (DNM2), transcript variant 4 NM_0010053
  • gil 113430465 Similar to ataxin 7-like 3 (LOC392485) X _018762 gil22219473 Fas (TNFRSF6) -associated via death domain (FADD) NM_003824 gil71361681 Nuclear mitotic apparatus protein 1 (NUMA1) NM_006185 gil20336312 B-cell CLL / lymphoma 11A (zinc finger protein) (BCL11A), transcript NM_138559

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
EP12708501.7A 2011-02-13 2012-02-13 Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation Withdrawn EP2673379A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12708501.7A EP2673379A2 (fr) 2011-02-13 2012-02-13 Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11154261A EP2487251A1 (fr) 2011-02-13 2011-02-13 Séquences de marqueur pour le diagnostic d'un carcinome de la prostate et leur utilisation
EP12708501.7A EP2673379A2 (fr) 2011-02-13 2012-02-13 Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation
PCT/EP2012/052438 WO2012107596A2 (fr) 2011-02-13 2012-02-13 Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation

Publications (1)

Publication Number Publication Date
EP2673379A2 true EP2673379A2 (fr) 2013-12-18

Family

ID=44681474

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11154261A Withdrawn EP2487251A1 (fr) 2011-02-13 2011-02-13 Séquences de marqueur pour le diagnostic d'un carcinome de la prostate et leur utilisation
EP12708501.7A Withdrawn EP2673379A2 (fr) 2011-02-13 2012-02-13 Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11154261A Withdrawn EP2487251A1 (fr) 2011-02-13 2011-02-13 Séquences de marqueur pour le diagnostic d'un carcinome de la prostate et leur utilisation

Country Status (3)

Country Link
US (1) US20140179557A1 (fr)
EP (2) EP2487251A1 (fr)
WO (1) WO2012107596A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110456065B (zh) * 2019-07-31 2022-09-09 四川大学华西医院 Ccdc130自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN120945045A (zh) * 2025-10-13 2025-11-14 武汉大学中南医院 Ufc1作为生物标志物在制备用于诊断和/或治疗前列腺增生的试剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101333530A (zh) * 2007-06-29 2008-12-31 上海交通大学医学院附属仁济医院 一种凋亡相关基因及以其为靶点用于治疗白血病的药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649420B1 (en) * 1997-08-26 2003-11-18 Thomas L. Cantor Methods and devices for detecting no-complexed prostate specific I antigen
DE69921982T2 (de) 1998-04-30 2005-12-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
WO1999057312A1 (fr) 1998-04-30 1999-11-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede permettant la selection de clones dans une banque d'expression et comprenant un rearrangement
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
AU2002226912A1 (en) * 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
EP1549938A4 (fr) * 2002-04-26 2010-05-12 Univ Johns Hopkins Identification de marqueurs biologiques pour la detection du cancer de la prostate
US20060088894A1 (en) * 2002-05-10 2006-04-27 Eastern Virginia Medical School Prostate cancer biomarkers
WO2006106129A2 (fr) * 2005-04-07 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Marqueurs polypeptidiques pour diagnostiquer le cancer de la prostate
WO2006116381A2 (fr) * 2005-04-22 2006-11-02 Imquest Biosciences, Inc. Fraction plasmique ou serique pour traitement ou prevention des proliferations cellulaires anormales
CA2680556A1 (fr) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarqueurs du cancer de la prostate et utilisations de ceux-ci
DE102007062847A1 (de) * 2007-12-21 2009-12-31 Protagen Ag Markersequenzen für neurodegenerative Erkrankungen und deren Verwendung
DE102008031699A1 (de) 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
US20120021925A1 (en) * 2009-01-19 2012-01-26 Miraculins, Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101333530A (zh) * 2007-06-29 2008-12-31 上海交通大学医学院附属仁济医院 一种凋亡相关基因及以其为靶点用于治疗白血病的药物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "GeneAnnot results for the Gene Symbol CHMP5 for HG-U95, HG-U133 and HG-U133 Plus 2.0", 1 October 2015 (2015-10-01), XP055217523, Retrieved from the Internet <URL:http://genecards.weizmann.ac.il/cgi-bin/geneannot/GA_search.pl> [retrieved on 20151001] *
ANONYMOUS: "GSN:AVA11449", 31 December 2008 (2008-12-31), XP055217700, Retrieved from the Internet <URL:http://ibis.internal.epo.org/exam/dbfetch.jsp?id=GSN:AVA11449> [retrieved on 20151001] *
KERNS S L ET AL: "Homo sapiens chromatin modifying protein 5 (CHMP5), transcript variant 1, mRNA", INT. J. RADIAT. ONCOL. BIOL. PHYS. 78 (5), 1292-1300 (2010), 29 January 2011 (2011-01-29), XP055217540, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/nuccore/306966144?sat=14&satkey=5310551> [retrieved on 20151001] *
SHAHMORADGOLI M ET AL: "Antiapoptotic function of charged multivesicular body protein 5: A potentially relevant gene in acute myeloid leukemia", INTERNATIONAL JOURNAL OF CANCER, vol. 128, no. 12, 23 August 2010 (2010-08-23), pages 2865 - 2871, XP055217657, ISSN: 0020-7136, DOI: 10.1002/ijc.25632 *
SHI T ET AL: "cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 10, 1 October 2010 (2010-10-01), pages E13054 - 1, XP002635543, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0013054 *
WANG H-R ET AL: "PNAS-2: a novel gene probably participating in leukemogenesis.", ONCOLOGY, vol. 71, no. 5-6, 2006, pages 423 - 429, XP009186394, ISSN: 1423-0232 *
XU LEI ET AL: "Merging microarray data from separate breast cancer studies provides a robust prognostic test", BMC BIOINFORMATICS, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 27 February 2008 (2008-02-27), pages 125, XP021031690, ISSN: 1471-2105 *

Also Published As

Publication number Publication date
WO2012107596A2 (fr) 2012-08-16
EP2487251A1 (fr) 2012-08-15
US20140179557A1 (en) 2014-06-26
WO2012107596A3 (fr) 2013-03-28

Similar Documents

Publication Publication Date Title
EP2483690A1 (fr) Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation
EP2795332A2 (fr) Séquences de marqueurs du cancer du sein et utilisation desdites séquences de marqueurs du cancer du sein
EP2791681A2 (fr) Procédé d&#39;identification de séquences de marqueurs pour le cancer gynécologique
KR20140042331A (ko) 인지장애 질환 진단용 다중 마커 및 그 용도
WO2010000874A2 (fr) Séquences de marqueurs pour maladies inflammatoires de la prostate, le cancer de la prostate, et leurs utilisations
EP2441848A1 (fr) Séquences de marqueur pour le lupus érythémateux systémique et son utilisation
WO2013170994A1 (fr) Séquences marqueurs de la polyarthrite rhumatoïde
WO2009030226A2 (fr) Séquences de marqueurs de la polyarthrite rhumatoïde et leur utilisation
KR101390543B1 (ko) 췌장암 진단용 마커 및 이의 용도
EP2622350A2 (fr) Séquences de marqueurs pour la sclérose multiple et utilisation desdites séquences de marqueurs
WO2009080017A2 (fr) Séquences de marqueurs pour des maladies neurodégénératives et leur utilisation
EP2673379A2 (fr) Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation
EP2772759A1 (fr) Composition pour diagnostic du cancer des poumons
WO2012041494A1 (fr) Diagnostic différentiel d&#39;adénomes du pancréas
EP2780471A2 (fr) Nouveau procédé d&#39;identification de séquences de marqueurs spécifiques pour le cancer de la prostate
EP2201132A2 (fr) Séquences de marqueurs de la sclérose en plaques et leur utilisation
EP2644704A1 (fr) Séquences de marqueurs pour l&#39;arthrite rhumatoïde
WO2012049228A2 (fr) Séquences de marqueur pour la sclérose en plaques et leur utilisation
WO2011006909A2 (fr) Séquences de marqueurs de l&#39;obésité et utilisation de ces séquences
DE102015108523A1 (de) Peptid-Biomarker für Krebs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130930

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

17Q First examination report despatched

Effective date: 20151009

B565 Issuance of search results under rule 164(2) epc

Effective date: 20151009

PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

17Q First examination report despatched

Effective date: 20151201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170901